WO2023084388 - METHODS FOR DETERMINING THE BIOLOGICAL ACTIVITY OF ANGPTL POLYPEPTIDES
National phase entry is expected:
Publication Number
WO/2023/084388
Publication Date
19.05.2023
International Application No.
PCT/IB2022/060727
International Filing Date
08.11.2022
Title **
[English]
METHODS FOR DETERMINING THE BIOLOGICAL ACTIVITY OF ANGPTL POLYPEPTIDES
[French]
PROCÉDÉS DE DÉTERMINATION DE L'ACTIVITÉ BIOLOGIQUE DE POLYPEPTIDES ANGPTL
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
HALLEUX, Christine Simone Aline
Novartis Pharma AG
Postfach
4002 Basel, CH
JACOBI, Carsten
Novartis Pharma AG
Postfach
4002 Basel, CH
Priority Data
63/277,852
10.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1294 | |
| EPO | Filing, Examination | 7046 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3035 |
Total: 12543 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods for assaying the chondrogenesis-inducing activity of a therapeutic by measuring the expression and/or secretion levels of chondrogenesis biomarkers.[French]
L'invention concerne des procédés d'analyse de l'activité induisant la chondrogenèse d'un agent thérapeutique par mesure des niveaux d'expression et/ou de sécrétion de biomarqueurs de la chondrogenèse.